Skip to main content

Table 1 Correlation between IER3 expression and clinicopathologic characteristics of HCC patients

From: TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3

Characteristics IER3 No. of cases (%) IER3 expreesion
Low or none, no. cases High, no. cases Statistic (c2) p value
Age
  < 50 37 (41.1) 14 23 1.509 0.219
  ≥ 50 53 (58.9) 27 26
Gender
 Male 80 (88.9) 37 43 0.14 0.708
 Female 10 (11.1) 4 6
HBsAg
 Positive 70 (77.8) 29 41 2.84 0.092
 Negative 19 (21.1) 12 7
HBcAb
 Positive 80 (88.9) 35 45 1.985 0.159
 Negative 7 (7.8) 5 2
HCV
 Positive 1 (1.1) 0 1 0.861 0.353
 Negative 86 (95.6) 40 46
Liver cirrhosis
 Yes 80 (88.9) 38 42 0.09 0.419
 No 9 (10.0) 3 6
Total bilirubin (mmol/L)
  < 21 75 (83.3) 36 39 0.717 0.397
  ≥ 21 14 (15.6) 5 9
ALT (U/L)      
  < 60 70 (77.8) 29 41 2.84 0.092
  ≥ 60 19 (21.1) 12 7
GGT (U/L)
  < 40 30 (33.3) 9 21 4.702 0.030
  ≥ 40 59 (65.6) 32 27
AFP (ng/L)
  < 20 36 (40.0) 17 19 0.067 0.795
  ≥ 20 54 (60.0) 24 30
Cirrhotic nodules
 Single 10 (11.1) 5 5 0.653 0.765
 Multiple 80 (88.9) 36 44
Vascular invasion
 Yes 21 (23.3) 12 9 1.545 0.214
 No 58 (64.4) 24 34
Tumor number
 Single 79 (87.8) 36 43 0 0.994
 Multiple 11 (12.2) 5 6
Tumor size
  < 5 cm 55 (61.1) 16 39 15.458  < 0.001
  ≥ 5 cm 35 (38.9) 25 10
Recrudescence
 Yes 49 (54.4) 27 22 3.952 0.047
 No 41 (45.6) 14 27
AJCC TNM stage
 I stage 58 (64.4) 24 34 1.392 0.499
 II stage 29 (32.2) 15 14
 III stage 3 (33.3) 2 1
  1. P values were calculated using chi-square test. Italics numbers indicate significant differences (P < 0.05)
  2. HCC hepatocellular carcinoma, HBsAg hepatitis B surface antigen, HBcAb hepatitis B core antigen, HCV hepatitis C virus, ALT alanine transaminase, GGT Gamma-Glutamyltransferase, AFP α-fetoprotein, AJCC the American Joint Committee on Cancer, TNM tumor-node-metastasis